SDZ ENA 713 facilitates central cholinergic function and ameliorates spatial memory impairment in rats

Area of Science:

• Neuroscience
• Pharmacology
• Cognitive Science

Background:

• Spatial learning deficits are often linked to cholinergic system dysfunction.
• Basal forebrain (BF) lesions in rats impair water maze performance and reduce choline acetyltransferase (ChAT) activity.
• SDZ ENA 713 (ENA) is a novel phenyl-carbamate derivative with potential cognitive-enhancing properties.

Purpose of the Study:

• To investigate the effects of ENA on spatial learning impairment in a rat model.
• To examine ENA's impact on neurochemical indices of central cholinergic neurons.

Main Methods:

• Rats underwent basal forebrain (BF) lesioning using ibotenic acid.
• Spatial learning was assessed using the water maze task.
• Choline acetyltransferase (ChAT) activity and extracellular acetylcholine (ACh) levels were measured.
• Effects of ENA administration (0.1, 0.2 mg/kg, p.o.) were evaluated in lesioned and normal rats.

Main Results:

• BF lesioning impaired acquisition ability in the water maze and decreased ChAT activity.
• ENA significantly ameliorated spatial learning deficits in a dose-dependent manner.
• ENA (0.2 mg/kg) prevented the reduction in ChAT activity and increased extracellular ACh in normal rats.
• Other neurotransmitter levels (norepinephrine, serotonin, dopamine) remained unchanged.

Conclusions:

• ENA ameliorates spatial learning disability in a rat model.
• The drug facilitates cholinergic transmission and normalizes impaired ChAT activity.
• ENA shows therapeutic potential for cognitive impairments associated with cholinergic deficits.